ClinicalTrials.gg
RecruitingNCT06525064Updated Jul 15, 2026

Health-E You Efficacy Trial for Male Adolescents

An interventional study of Health-E You app in Sexually Transmitted Diseases, Sexual Health and Reproductive Health, sponsored by Johns Hopkins University. Recruiting at 8 sites in United States. Open to male participants aged 13 Years to 21 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-15.

Sponsored by Johns Hopkins University · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2,752
Allocation
Randomized
Ages
13 Years to 21 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 283 studies in Sexually Transmitted Diseases with a site in United States — 32 open to participants now, 42 under way, 1 of them phase 3. Sexually Transmitted Diseases · United States.

Planned enrollment
18th of 251
2,752 · median 400
Started
2026
with 11 others
No phase
190 of 283
24 open now
Primary completion
2028-05
later than 29 of 41 live
Registered
256th of 283
by date

Among the 283 studies in Sexually Transmitted Diseases with a site in United States, this one is the 18th largest by planned enrollment of the 251 interventional ones that give a count, is one of 12 that started in 2026, is one of 190 with no phase, reaches primary completion later than 29 of the 41 other live ones, and was the 256th registered.

Sexually Transmitted Diseases

525 studies on the registry are indexed under Sexually Transmitted Diseases; 79 are open to participants now.

Browse Sexually Transmitted Diseases studies →

Open to participants now

32 of the 283 studies in Sexually Transmitted Diseases with a site in United States are open now. Recruiting first, the newest first:

26 more — sign in →

All 32 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 49 Sexually Transmitted Diseases studies recruiting now, 30 (61%) set no upper age limit and 17 (35%) stop at 75 or younger; 23 take children under 18; 33 take healthy volunteers.

This study: 13 Years to 21 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 283 studies in Sexually Transmitted Diseases with a site in United States, or all of them as a file.
02

Study summary

This study will involve evaluating Health-E You/Salud ìTu™, a web-based, pre-visit mobile app designed to support adolescent male youth and his clinicians in discussing sexual and reproductive health (SRH) topics and care. It will test its efficacy among male patients in clinical settings using a stepped wedge cluster randomized controlled trial design.

Read the detailed description

Health-E You is a pre-visit, web-based mobile app designed to support an adolescent male youth and his clinician in discussing SRH topics and care. It is shared with an adolescent patient prior to a clinic visit, and contains initial questions that subsequently provide the patient with individually-tailored health information. In addition, the app provides relevant information to the clinician on patients' SRH to optimize the time together as part of the visit. In total, the app takes approximately 10-15 minutes to complete. The purpose of this study is to evaluate the efficacy of the Health-E You app among male youth ages 13-21 using a cluster-randomized stepped-wedge design. A participant will be considered to have completed the study if the participant has completed the baseline assessment, worked through the app, an immediate follow-up assessment, and a 2-month post-visit follow-up assessment. The end of the study is defined as completion of the 2-month follow-up assessment. Hypotheses include compared to usual care, app users will have greater improvements in male method use behaviors (i.e., condom use) as well as knowledge about pregnancy and sexually transmitted infection (STI) prevention methods, male method use self-efficacy, improved knowledge about SRH care, self-efficacy talking with a clinician about SRH, beliefs about SRH promotion, and SRH care receipt.

03

Conditions studied

  • Sexually Transmitted Diseases
  • Sexual Health
  • Reproductive Health

Keywords

  • male adolescent
  • condom use
  • mhealth
04

Who can participate

Ages eligible
13 Years to 21 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Assigned male sex at birth
  • Age 13 to 21 years old
  • English and/or Spanish as preferred language to read, listen, and converse
  • Self-reported engagement in vaginal and/or anal sex in the past 12 months
  • Access to phone or internet for follow-up study activities

Exclusion criteria

Exclusion Criteria:

  • Aged 12 or younger or older than 21
  • Primary language other than English or Spanish
  • Not able to provide
  • Unable to communicate due to cognitive, mental, language, or other difficulties
  • Not sexually active, engaged in oral sex only, or more than 12 months have passed since last vaginal and/or anal sex.
  • Previous participation in a Health-E You study activity or the app
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
2,752 participants (estimated)

Study arms

  • No intervention
    Control Group

    When clinics are in the control condition, patients will receive usual care. Before the visit eligible participants will receive a weblink to study information, and if agree to participate, the survey. The participants will not be presented Health-E You content and clinicians will not receive output to prime the visit; the participants will receive usual care as typical. Previously enrolled control males will not be enrolled during intervention periods to maintain the research study's integrity.

  • Experimental
    Intervention Group

    When clinics are in the intervention condition, all patients presenting for any reason will get a study weblink 24 hours before the visit; walk-ins will get a study link code in clinic. If the participants agree to participate and meet study criteria, the participants will get a survey link and then Health-E You content to complete before the visit. Previously enrolled males will not be enrolled again to maintain the research study's integrity. Thus, participants will only have one opportunity for administration to the Health-E You app. Participants will be considered to have completed the Health-E You app if the participants answer all of the app's initial tailoring questions and receive recommendations for SRH topics to discuss with the clinician. As a technology-based intervention, no direct interactions with interventionists with participants are required.

    Other: Health-E You app

Interventions

  • OtherHealth-E You app

    When clinics are in the intervention condition, all patients presenting for any reason will get a study weblink 24 hours before the visit; walk-ins will get a study link code in clinic. If the participants agree to participate and meet study criteria, the participants will get a survey link and then Health-E You content to complete before the visit. Previously enrolled males will not be enrolled again to maintain the research study's integrity. Thus, participants will only have one opportunity for administration to the Health-E You app. Participants will be considered to have completed the Health-E You app if the participants answer all of the app's initial tailoring questions and receive recommendations for SRH topics to discuss with the clinician. As a technology-based intervention, no direct interactions with interventionists with participants are required.

06

What researchers measure

Primary outcomes

  1. Correct Condom Use Self-Efficacy Scale

    Higher score indicates greater self-efficacy for correct use of male condoms. This measure is scaled with range from 1 (very difficult) to 5 (very easy); range 7-35.

    Time frame: Baseline, 24 hours after visit, 2-month follow-up

  2. Perceived efficacy in patient-physician interactions (PEPPI)

    Higher score indicates greater efficacy in patient-physician interaction about sexual and reproductive health. This measure is scaled with range from 1 (not at all confident) to 5 (very confident); range 5-25.

    Time frame: Baseline, 24 hours after visit, 2-month follow-up

  3. Frequency condom use

    Measures frequency condom use with main \& non-main partners in past year and last 2 months

    Time frame: Baseline, 2-month follow-up

  4. Sexual and reproductive care receipt

    Measures receipt of the recommended sexual and reproductive care package, based on national guidelines outlined by the Centers for Disease Control and Prevention (CDC) Office of Population Affairs (OPA) Quality Family Planning guidance \& American Academy of Pediatrics' Bright Futures

    Time frame: Baseline, 24 hours after visit, 2-month follow-up

07

Study locations

8 of 8 sites recruiting
08

References and documents

Publications

  • Akande M, Aturaliya R, Osio Smith S, Smith A, Arrington-Sanders R, Tebb K, Marcell AV. Integrating Young Male Voices to Enhance Sexual and Reproductive Healthcare Uptake of Innovative Pre-Clinic Technology. Journal of Adolescent Health. 2024;74(3 Suppl):S2.
  • Tebb KP, Rodriguez F, Pollack LM, Adams S, Rico R, Renteria R, Trieu SL, Hwang L, Brindis CD, Ozer E, Puffer M. Improving contraceptive use among Latina adolescents: A cluster-randomized controlled trial evaluating an mHealth application, Health-E You/Salud iTu. Contraception. 2021 Sep;104(3):246-253. doi: 10.1016/j.contraception.2021.03.004. Epub 2021 Mar 17. PubMed 33744300 ↗
  • Marcell AV, Smith AD, Osio Smith S, Akande M, Rohlff S, Arrington-Sanders R, Tebb K. A Previsit Mobile Health App (Health-E You/Salud iTu) for Male Adolescents to Promote Sexual and Reproductive Health Care Receipt: Protocol for a Randomized Controlled Trial. JMIR Res Protoc. 2025 Oct 15;14:e77780. doi: 10.2196/77780. PubMed 41092393 ↗

Individual participant data

Plan to share: No — The final version of collected data will be made available within thirty (30) months after the end of the data collection. Data will be preserved and made accessible along with the data codebook and other relevant documentation via the chosen repository. The investigators will make the data available through restricted/controlled access. Open Inter-university Consortium for Political and Social Research's (ICPSR's) Traditional Restricted Data or Physical Data Enclave will be used for some or all of the data, with restricted access solely to approved researchers.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for May 2028, 23 months after the start.

Of 173 non-industry interventional studies with no phase under Sexually Transmitted Diseases, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 47. This study's planned 23 months is below that.

Counting every sponsor, half of 183 studies reached it within 31 months; a quarter within 16 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2024
First posted
Jul 29, 2024
StartActual
Jun 2, 2026
Primary completionEst.
May 2028
CompletionEst.
May 2028
Last update
Jul 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06525064
Responsible party
Sponsor
First posted
Jul 29, 2024
Start date
Jun 2, 2026
Primary completion
May 2028 (estimated)
Completion
May 2028 (estimated)
Last update
Jul 15, 2026

Study contacts

Arik V Marcell, MD, MPH
Contact
amarcell@jhu.edu
4432878946
Sofia Osio, MSPH
Contact
sosiosm1@jh.edu
Arik V Marcell, MD, MPH
principal investigator · Johns Hopkins Dept of Pediatrics / Division of Adolescent/Young Adult Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion